The long-acting needle-based combination of its drug cabotegravir and Janssen’s treatment rilpivirine met its main goal in the study, which was testing the regimen in adults with HIV-1 whose virus was suppressed.
GSK long-acting HIV injection succeeds in study
Saturday 24 12:19